Yoshida Hiroyuki

ヨシダヒロユキ | Yoshida Hiroyuki

Affiliation and department：
Job title： Professor

Research field (1)： Obstetrics and gynecology

Research keywords (1)：婦人科腫瘍

Research theme for competitive and other funds (4)：

2022 - Development of an AI-based model for predicting chemotherapy adverse events in elderly cancer patients.
2022 - Development of a novel therapy for PARP inhibitor-resistant ovarian cancer by targeting DNA helicases.
2017 - 2018 卵巣癌化学療法感受性におけるcopper transporterの関連
2016 - 2017 婦人科悪性腫瘍におけるDNA mismatch repair systemの異常に関する研究

Papers (110)：

Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, et al. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. European journal of cancer. 2023. 181. 42-52
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, et al. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. Journal of clinical oncology, precision oncology. 2023. e2200258
Kukimoto I, Onuki M, Yamamoto K, Yahata H, Aoki Y, Yokota H, Konnai K, Nio A, Takehara K, Kamiura S, et al. Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia. Japanese Journal of Clinical Oncology. 2022. 52. 10. 1242-1247
Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Harushige Yokota, Hisamori Kato, Kumi Shimamoto, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, et al. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. Cancer science. 2022. 113. 4. 1428-1434
Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, et al. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. Vaccines. 2022. 10. 2

ｍore...

MISC (21)：

吉田愛, 市村友季, 梶谷耕二, 吉田裕之, 松本佳也, 角俊幸, 本田謙一, 金岡靖, 石河修. P3-31 Ki-67およびCD34の発現を用いた子宮平滑筋肉腫の針生検診断の検討(Group79 子宮体部悪性腫瘍8,一般演題,第61回日本産科婦人科学会学術講演会). 日本産科婦人科學會雜誌. 2009. 61. 2. 678-678
松本佳也, 月岡美穂, 安部佳代子, 中野雄介, 梶谷耕二, 吉田愛, 吉田裕之, 市村友季, 角俊幸, 金岡靖, et al. P2-69 上皮性卵巣癌の組織型によるGSK-3αGSK-3βの発現様式の特徴(Group42 卵巣腫瘍7,一般演題,第61回日本産科婦人科学会学術講演会). 日本産科婦人科學會雜誌. 2009. 61. 2. 548-548
梶谷耕二, 本田謙一, 安部佳代子, 中野雄介, 吉田愛, 吉田裕之, 市村友季, 松本佳也, 角俊幸, 金岡靖, et al. P2-32 estrogen response element付加による癌抑制遺伝子p53の発現促進(Group37 子宮体部悪性腫瘍5,一般演題,第61回日本産科婦人科学会学術講演会). 日本産科婦人科學會雜誌. 2009. 61. 2. 536-536
安部佳代子, 吉田裕之, 中野雄介, 梶谷耕二, 吉田愛, 松本佳也, 市村友季, 角俊幸, 本田謙一, 金岡靖, et al. P1-62 血液透析中の卵巣癌患者におけるpaclitaxelおよびcarboplatinの体内動態に関する検討(Group9 卵巣腫瘍3,一般演題,第61回日本産科婦人科学会学術講演会). 日本産科婦人科學會雜誌. 2009. 61. 2. 466-466
吉田裕之, 角俊幸, 安部佳代子, 中野雄介, 梶谷耕二, 吉田愛, 松本佳也, 市村友季, 本田謙一, 金岡靖, et al. K1-17 卵巣癌におけるclaudin-4の発現と細胞遊走抑制効果の検討(高得点演題3 腫瘍,高得点演題プログラム,第61回日本産科婦人科学会学術講演会). 日本産科婦人科學會雜誌. 2009. 61. 2. 435-435

ｍore...

Lectures and oral presentations (3)：

高齢婦人科がん患者における化学療法有害事象予測ツールの有用性
(日本癌治療学会 2022)
Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial.
(ESMO CONGRESS 2021)
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial.
(The Society of Gynecologic Oncology 2021)

Education (2)：

1998 - 2002 Osaka City University Graduate School, Division of Medicine
1990 - 1996 Osaka City University Faculty of Medicine

Professional career (1)：

医学博士 (大阪市立大学)

Work history (11)：

2016/04 - 現在埼玉医科大学国際医療センター婦人科腫瘍科准教授
2016/04 - 現在 Associate Professor
2013/04 - 2016/03 Lecturer
2006/04 - 2013/03 Lecturer
2005/10 - 2006/03 Osaka City University Graduate School of Medicine

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page